Randomized, Open-label Economic and Medical Study on the Lymph Node Management of Squamous Cell Carcinoma of the Oral Cavity and Oropharynx Tumor Stage 1 or 2, Nodes 0 (T1-T2 N0) Operable
NCT02855723 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 307
Last updated 2016-08-04
Summary
Currently, patients with cancer of oral cavity or oropharynx T1-T2N0 classified, are treated surgically with systematic lymph node dissection while in 70%, there is no lymph node metastasis. The technique of identifying the sentinel node (GS) is validated for these tumors because the status of the sentinel node is predictive of the other nodes status in the neck. This helps to diagnose the presence of metastases without lymph node dissection and thus select patients requiring a treatment node. However, the oncological and functional results of a therapeutic strategy based on identifying the GS is unknown.
This open-label randomized multicenter clinical trial aims to compare the oncologic and functional outcome of two strategies : the current management versus the management based on the sentinel lymph node.
The hypothesis is based on a nodal control difference at 2 years in both arms not exceeding 10%. The medico-economic analysis will be conducted in two stages : a classic stage on 2 years with estimated incremental cost-effectiveness and incremental cost-utility, then a step with log term modeling.
A reduction in morbidity and treatment costs in the sentinel node arm are expected in this study.
Conditions
- Head and Neck Tumors
Interventions
- OTHER
-
Surgery: GS strategy
sentinel node biopsy
- OTHER
-
Surgery: Classic strategy
systematic lymphadenectomy
Sponsors & Collaborators
-
University Hospital, Montpellier
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2008-04-30
- Primary Completion
- 2015-08-31
- Completion
- 2015-08-31
Countries
- France
Study Locations
More Related Trials
-
Prognostic Significance of Lymph Node Yield and Lymph Node Ratio Prospective Observational Study
NCT03534778 ·Status: UNKNOWN
-
Anti-tumor Specific Immune Response in Head and Neck Cancers
NCT02881918 ·Status: UNKNOWN
-
Primary Tumor Depth of Invasion and Lymph Node Management in Oral Squamous Cell Carcinoma
NCT07127614 ·Status: NOT_YET_RECRUITING
-
A Study on Tumor Budding Guiding Individualized Surgical Planning of Early-stage Oral Squamous Cell Carcinoma.
NCT02743832 ·Status: RECRUITING ·Phase: NA
-
A Phase II Study to Evaluate the Efficacy and Safety of Salvage Preoperative PD-1 Inhibitor Combined with Chemotherapy Neoadjuvant Therapy in Recurrent and Metastatic LPSCC/HPSCC
NCT06793761 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma
NCT04124198 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Induction Modified TPF Followed by Concurrent Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
NCT05527782 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck
NCT04664582 ·Status: UNKNOWN ·Phase: NA
-
Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer
NCT05800574 ·Status: RECRUITING ·Phase: PHASE2
-
Phase 2 Pragmatic Trial of Sentinel Lymph Node Biopsy (SLNB) in Patients With Clinically Node-Negative (cN0), High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) of the Head and Neck
NCT06990737 ·Status: RECRUITING ·Phase: PHASE2
-
Profile of Plasma Growth Factors Before and After Head and Neck Oncological or Non-oncological Surgery
NCT01280318 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
NCT00939627 ·Status: COMPLETED ·Phase: PHASE2
-
The Role of Micrometastasis and Isolated Tumor Cells (ITCs) in Endometrial and Cervical Cancer. A Multicenter Study.
NCT04403867 ·Status: RECRUITING
-
The Management of Metastatic Neck Nodes in N2/3 Hypopharyngeal Squamous Cell Carcinoma
NCT05494190 ·Status: RECRUITING ·Phase: NA
-
Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck
NCT03132038 ·Status: COMPLETED ·Phase: PHASE2
-
NODE (groiN ultrasOunD cancEr)
NCT06264167 ·Status: RECRUITING ·Phase: NA
-
Radiotherapy With Cisplatin Versus Radiotherapy With Cetuximab After Induction Chemotherapy for Larynx Preservation
NCT00169247 ·Status: COMPLETED ·Phase: PHASE2
-
Maintenance Tegafur-uracil in Resected Oral Cavity Cancer With ECS+
NCT03121313 ·Status: UNKNOWN ·Phase: PHASE2
-
Definitive Chemo-Radiotherapy for Regionally Advanced Head and Neck Cancer With or Without Up-front Neck Dissection
NCT02918955 ·Status: COMPLETED ·Phase: PHASE3
-
Study Assessing The "Best of" Radiotherapy vs the "Best of" Surgery in Patients With Oropharyngeal Carcinoma
NCT02984410 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Dose De-escalation and Sentinel LN Mapping Driven Radiotherapy of Contralateral Neck in Ipsilateral Node Positive HNSCC
NCT04688528 ·Status: RECRUITING ·Phase: NA
-
Optimised Early Management of Squamous Cell Carcinoma of the Head and Neck Cancer
NCT04528420 ·Status: RECRUITING ·Phase: NA
-
Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers
NCT04747054 ·Status: RECRUITING ·Phase: PHASE3
-
Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy
NCT01256385 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck
NCT01577173 ·Status: COMPLETED ·Phase: PHASE2